Keywords: Hematology, Oncology, Toxicity, Cardiac magnetic resonance, anthracycline, cardiotoxicity
Motivation: To identify cancer therapy-related cardiac dysfunction (CTRCD) in patients with breast cancer (BC) receiving anthracycline
Goal(s): To evaluate longitudinal changes in myocardial T2* and investigate the utility of T2* mapping for identifying CTRCD
Approach: Seventy-eight participants with BC receiving anthracyclines were recruited. All participants underwent CMR at baseline, about 3 months and 6months. T2*, T1, T2 and strain were measured and compared. Logistic regression analysis and receiver operating characteristic analysis were used to assess the performance of T2* values in predicting CTRCD
Results: T2* decreased, T1 and T2 increased in patients with BC receiving anthracyclines. T2* can predict subsequent CTRCD in these patients.
Impact: Myocardial T2* mapping can identify subsequent CTRCD in patients with BC receiving anthracyclines with/without trastuzumab. This may facilitate accurate prediction of cardiotoxicity and personalized treatment decision making in breast cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords